See more : TechnipFMC plc (FTI) Income Statement Analysis – Financial Results
Complete financial analysis of Rain Therapeutics Inc. (RAIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rain Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sanginita Chemicals Limited (SANGINITA.NS) Income Statement Analysis – Financial Results
- Q & M Dental Group (Singapore) Limited (QC7.SI) Income Statement Analysis – Financial Results
- Saunders International Limited (SND.AX) Income Statement Analysis – Financial Results
- A. H. Belo Corporation (AHC) Income Statement Analysis – Financial Results
- Takara Leben Real Estate Investment Corporation (3492.T) Income Statement Analysis – Financial Results
Rain Therapeutics Inc. (RAIN)
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.40M | 40.77M | 15.37M | 7.29M |
| General & Administrative | 15.74M | 10.74M | 3.59M | 3.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74M | 10.74M | 3.59M | 3.54M |
| Other Expenses | 0.00 | 1.00K | -2.02M | -251.00K |
| Operating Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Cost & Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Interest Income | 1.42M | 119.00K | 32.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 135.00K | 32.00K |
| Depreciation & Amortization | 80.00K | 120.00K | -1.94M | -14.00K |
| EBITDA | -77.06M | -51.51M | -18.91M | -10.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -77.14M | -51.51M | -18.96M | -10.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 120.00K | -2.13M | -74.00K |
| Income Before Tax | -75.72M | -51.39M | -21.08M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -1.89M | -219.00K |
| Net Income | -75.72M | -51.39M | -19.20M | -10.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.71 | -2.65 | -1.80 | -1.00 |
| EPS Diluted | -2.71 | -2.65 | -1.80 | -1.00 |
| Weighted Avg Shares Out | 27.99M | 19.41M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 27.99M | 19.41M | 10.66M | 10.66M |
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $RAIN #RAIN--The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm.
The Law Offices of Frank R. Cruz Announces Investigation of Rain Oncology Inc. (RAIN) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Rain Oncology Inc. (“Rain” or the “Company”) (NASDAQ: RAIN) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder...
Monish Pabrai on Finding Multi-Baggers and Intrinsic Valuation
Mohnish Pabrai (Trades, Portfolio) is a legendary investor and the founder of Pabrai funds.
Calling All Rain Oncology Inc. (RAIN) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
NEW YORK--(BUSINESS WIRE)---- $RAIN #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rain Oncology Inc. ("Rain" or “the Company”) (NASDAQ: RAIN) and certain of its...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of §§10(b)...
RAIN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 12, 2023 in the Class Action Filed on Behalf of Rain Oncology Inc. Shareholders
NEW YORK , July 18, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN) alleging that the Company violated federal securities laws. Class...
Calling All Rain Oncology Inc. (RAIN) Investors: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Class Action Lawsuit!
NEW YORK , July 17, 2023 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ: RAIN)...
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Rain Oncology Inc. (RAIN)
SAN DIEGO--(BUSINESS WIRE)---- $RAIN #MANTRAtrial--Rain Oncology Inc. (RAIN) Misled Investors Regarding the Viability of its Lead Drug Candidate Milademetan.
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Rain Oncology Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ: RAIN)...
Source: https://incomestatements.info
Category: Stock Reports